Feuille Elizabeth, Nowak-Węgrzyn Anna
Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, Kravis Children's Hospital, New York, N.Y., USA.
Ann Nutr Metab. 2016;68 Suppl 1:19-31. doi: 10.1159/000445391. Epub 2016 Jun 30.
Oral immunotherapy (OIT) is a promising investigational therapy for food allergy. Clinical trials in peanut, milk, egg, and wheat allergy provide evidence that OIT can effectively desensitize a majority of individuals to a food allergen. While a portion of subjects demonstrate sustained unresponsiveness, the majority regain sensitivity with allergen avoidance. The safety and tolerability of OIT continue to limit its use in some patients. Virtually all studies report adverse reactions that are more frequent during dose escalation but may also occur during maintenance therapy. Recent studies have identified adjunctive therapies (such as omalizumab) which may mitigate adverse effects. There is a paucity of data on the long-term safety and efficacy of OIT. Further study is required before OIT is ready for routine clinical practice. This review is intended to provide the reader with an up-to-date understanding of OIT, including its mechanisms, efficacy, safety profile, and potential utility in clinical practice.
口服免疫疗法(OIT)是一种针对食物过敏颇具前景的试验性疗法。针对花生、牛奶、鸡蛋和小麦过敏的临床试验表明,OIT能够有效使大多数个体对食物过敏原产生脱敏作用。虽然一部分受试者表现出持续无反应性,但大多数人在避免接触过敏原后会重新恢复敏感性。OIT的安全性和耐受性仍然限制了其在某些患者中的应用。几乎所有研究都报告了不良反应,这些反应在剂量递增期间更为频繁,但在维持治疗期间也可能发生。最近的研究已经确定了辅助疗法(如奥马珠单抗),其可能减轻不良反应。关于OIT长期安全性和有效性的数据匮乏。在OIT准备好用于常规临床实践之前,还需要进一步研究。本综述旨在让读者对OIT有最新的了解,包括其机制、疗效、安全性概况以及在临床实践中的潜在用途。